Discontinued Product Liability and Occurrence CGLs
A manufacturer sold a division of the business. Is discontinued products liability necessary, or will the ongoing CGL cover the liability for the products manufactured and sold before the sale?
A manufacturer sold a division of the business. Is discontinued products liability necessary, or will the ongoing CGL cover the liability for the products manufactured and sold before the sale?
As the directors & officers (D&O) market shifts from soft to hard, it is a prime time for independent agents to identify emerging trends and changing exposures for their clients.
While D&O and cyber liability policies offer distinct coverage differences, many companies mistakenly believe they do not require separate policies.
To mitigate the risk of an errors & omissions claim, insurance professionals need to approach offering umbrella coverage with diligence and consistency.
Coverage will help medical technology, pharmaceutical, biopharmaceutical and digital health companies with the costs of product-related claims.
Proactive conversations with clients about catastrophe risks can surface potential coverage gaps and open the door to more forward-looking planning.
Agents must strike a balance between recommending suitable coverage and refraining from providing opinions on whether specific losses are covered under a given policy.
As trusted advisors, agents can identify the trends in specific types of professional services, understand the risks and translate them for their clients
Rising costs within the sector threaten coverage affordability and, in the long run, availability. Yet, insureds still need coverage.
The excess policy provides follow-form coverage on professional liability coverage with limits up to $5 million and a minimum attachment point of $500,000.